Lucid Diligence Brief - Tech

Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration

Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Anthropic acquires Coefficient Bio

Lucid Diligence Brief: Anthropic acquires Coefficient Bio Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership

Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset

Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……


Lucid Diligence Brief - Tech

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD

Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: MSD to acquire Terns

Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…


Privacy Preference Center